 |
7 Diseases |  |
13 Trials |
|
13 Trials |  |
1459 News |  |
| «12...345678910111213...1617» |
- | Journal: Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison. (Pubmed Central) - Oct 27, 2021
Indirect treatment comparison showed no statistically significant differences in reduction of ≥ 50% migraine days/month between erenumab, fremanezumab and eptinezumab. Probable clinical equivalence was found between these drugs in terms of efficacy and safety, therefore they could be considered equivalent therapeutic alternatives in chronic migraine.
- || Ajovy (fremanezumab) / Otsuka, Teva
My Ajovy got delayed then @BlueKC decided they needed a PA for that and wouldn't cover Trokendi at all. But they did pay $3k for me to get some compazine and toradol at the ER which takes under an hour . 🤷🏻♀️ (Twitter) - Oct 26, 2021
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Reductions in Migraine Frequency with Fremanezumab Treatment by Baseline Migraine Frequency Category in Patients with Chronic and Episodic Migraine () - Oct 21, 2021 - Abstract #ANA2021ANA_264;
Probable clinical equivalence was found between these drugs in terms of efficacy and safety, therefore they could be considered equivalent therapeutic alternatives in chronic migraine. Treatment with quarterly and monthly fremanezumab was associated with greater reductions in migraine frequency compared with placebo, regardless of migraine frequency at baseline.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Efficacy of Long-Term Fremanezumab Treatment in Patients with Chronic or Episodic Migraine and Prior Inadequate Response to Multiple Migraine Preventive Medication Classes () - Oct 21, 2021 - Abstract #ANA2021ANA_262;
Treatment with quarterly and monthly fremanezumab was associated with greater reductions in migraine frequency compared with placebo, regardless of migraine frequency at baseline. Fremanezumab demonstrated long-term efficacy in CM and EM patients with prior inadequate response to multiple preventive classes, including those switching from quarterly to monthly fremanezumab.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Biomarker, Clinical, Journal: CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab. (Pubmed Central) - Oct 14, 2021
Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.
- |||| Ajovy (fremanezumab-vfrm) / Teva
Trial completion date, Trial primary completion date: A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Oct 4, 2021
P3, N=288, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker. Trial completion date: Dec 2023 --> Dec 2022 | Trial primary completion date: Dec 2023 --> Dec 2022
- ||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, Adverse events: Letter to the editor regarding "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database". (Pubmed Central) - Sep 30, 2021
Trial completion date: Dec 2023 --> Dec 2022 | Trial primary completion date: Dec 2023 --> Dec 2022 No abstract available
- ||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, Adverse events: Reply to the Letter to the Editor by Kessler Y et al. regarding the manuscript "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database." (Pubmed Central) - Sep 30, 2021
No abstract available No abstract available
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal: Fremanezumab autoinjector pen for the prevention of migraine. (Pubmed Central) - Sep 29, 2021
It is indicated for prophylaxis of migraine in adults who have at least four migraine days per month, and can be administered as a subcutaneous injection using an autoinjector device, with two dosing options: 225 mg once a month or 675 mg quarterly. In this article, I present data from Phase III clinical trials of fremanezumab in episodic and chronic migraine, in which fremanezumab demonstrated efficacy and had a favorable tolerability profile, with no serious treatment-related adverse events.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Retrospective data, Journal, Real-world evidence: CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. (Pubmed Central) - Sep 22, 2021
In this article, I present data from Phase III clinical trials of fremanezumab in episodic and chronic migraine, in which fremanezumab demonstrated efficacy and had a favorable tolerability profile, with no serious treatment-related adverse events. Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache.
- || Ajovy (fremanezumab) / Otsuka, Teva
Review, Journal: Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? (Pubmed Central) - Sep 22, 2021
There is currently only indirect preclinical evidence to support a rationale for dual therapy with anti-calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A for chronic migraine prevention. Rigorous studies evaluating clinical efficacy, safety, and cost-effectiveness are needed.
- || Ajovy (fremanezumab) / Otsuka, Teva
Clinical, Journal: Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses. (Pubmed Central) - Sep 22, 2021
Rigorous studies evaluating clinical efficacy, safety, and cost-effectiveness are needed. Exposure-response evaluations showed that both monthly (225 mg) and quarterly (675 mg) fremanezumab dosing regimens were appropriate in achieving clinical benefit in adult patients with EM or CM.
- Ajovy (fremanezumab) / Otsuka, Teva
Pooled Analysis of the Efficacy of Fremanezumab for Reducing Disability and Acute Medication Overuse in Migraine Patients Overusing Migraine-specific Acute Medications at Baseline () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_64;
At week 12, a significantly higher proportion of patients reverted to no medication overuse with quarterly fremanezumab (53%) and monthly fremanezumab (61%) versus placebo (28%; both P < 0.0001). Conclusion : Treatment with fremanezumab was effective and resulted in significant reductions in the monthly average number of migraine days, disability, and overuse of acute migraine-specific abortive medications, demonstrating the benefits of fremanezumab in those with overuse of MSAM.
- Patient clinical characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_60;
The most common comorbid conditions were anxiety, depression, sleep disorder, hypertension, gastroesophageal reflux disease, sinusitis, and fatigue. Understanding the demographic and clinical characteristics of patients who initiate a self-injectable CGRP and novel acute medication for migraine as well as treatment utilization may provide valuable insight about treatment selection for migraine to clinicians and other healthcare decision makers.
- | Journal: The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms. (Pubmed Central) - Sep 5, 2021
Unfortunately, further pharmaceutical development (for olcegepant and telcagepant) was interrupted due to pharmacokinetic issues observed during the Randomized Clinical Trials (RCT)...Presently, the U.S. Food and Drug Administration approved four mAbs, namely: (i) erenumab; (ii) fremanezumab; (iii) galcanezumab; and (iv) eptinezumab...Since these mAbs have a molecular weight of 150 kDa, some studies rule out the relevance of their central actions as they seem unlikely to cross the blood-brain barrier (BBB). Considering the therapeutic relevance of this new class of antimigraine compounds, the present review has attempted to summarize and discuss the current evidence on the probable sites of action of these mAbs.
- || Ajovy (fremanezumab) / Otsuka, Teva
Clinical, Journal: Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine. (Pubmed Central) - Aug 28, 2021
P3
Considering the therapeutic relevance of this new class of antimigraine compounds, the present review has attempted to summarize and discuss the current evidence on the probable sites of action of these mAbs. Fremanezumab reduced the need for acute headache medications, including migraine-specific medications, while treating migraine-associated symptoms in patients with episodic migraine.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Review, Journal, HEOR: Quality of Life Related to Functional Disability in Migraine Patients: A Systematic Review and Network-meta Analysis. (Pubmed Central) - Aug 24, 2021
Fremanezumab reduced the need for acute headache medications, including migraine-specific medications, while treating migraine-associated symptoms in patients with episodic migraine. For short term prevention of migraine, fremanezumab demonstrated slightly better improvement in disability compared with other anti-CGRP mAbs in adult patients with migraine.
- || Ajovy (fremanezumab) / Otsuka, Teva
Trial initiation date: Fremanezumab, Migraine and Sleep (clinicaltrials.gov) - Aug 18, 2021
P4, N=100, Not yet recruiting, Sponsor: Beth Israel Deaconess Medical Center
For short term prevention of migraine, fremanezumab demonstrated slightly better improvement in disability compared with other anti-CGRP mAbs in adult patients with migraine. Initiation date: Feb 2021 --> Aug 2021
- |||| Ajovy (fremanezumab-vfrm) / Teva
Trial completion date, Trial primary completion date: A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Aug 18, 2021
P3, N=288, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Initiation date: Feb 2021 --> Aug 2021 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Retrospective data, Review, Journal: Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. (Pubmed Central) - Aug 13, 2021
The analysis of combined groups data (Chronic and Episodic) showed that Fremanezumab was the most effective drug after six weeks, where Erenumab was the most effective after 8 and 12 weeks. The current evidence retrieved from this NMA suggests that Fremanezumab was the most effective anti-migraine medication in decreasing MHDs per month after six weeks in both chronic and episodic patients.
- || Clinical, Review, Journal, HEOR, Real-world evidence: Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far? (Pubmed Central) - Aug 7, 2021
Large scale randomized clinical trials confirmed that inhibition of the CGRP system attenuates migraine, while the PACAP mediated nociception is still under scientific and clinical investigation. In this review, we provide the latest clinical evidence for the use of anti-CGRP in migraine prevention with emphasis on efficacy and safety outcomes from Phase III and real-world studies.
- Ajovy (fremanezumab) / Otsuka, Teva, atogepant (AGN-241689) / AbbVie
[VIRTUAL] PERIPHERAL AND CENTRAL MECHANISMS OF MIGRAINE PROVIDE RATIONALE FOR COMBINATION THERAPY (Main Topic A) - Aug 6, 2021 - Abstract #WCN2021WCN_789;
A similar pattern was seen in responses to mechanical stimulation of the dura and skin. Given BoNT-A preferential inhibitory effects on unmyelinated C- but not thinly myelinated Ad-fibers, and fremanezumab preferential inhibitory effects on Ad- but not C-fibers, it is reasonable to propose that the robust inhibition of activation and sensitization of the HT and WDR trigeminovascular neurons by the BoNT-A/ATO combination treatment was achieved through a dual blockade of both classes of meningeal nociceptors.
- || Review, Journal: Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. (Pubmed Central) - Aug 6, 2021
Putting the CGRP/rec mAbs in perspective with available preventive migraine drug treatments, their major advantage seems not to be chiefly their superior efficacy but their unprecedented efficacy over adverse event ratio. Regarding cost-effectiveness, preliminary pharmaco-economic analyses of erenumab suggest that it is cost-effective for chronic migraine compared to no treatment or to onabotulinumtoxinA, but likely not for episodic migraine unless attack frequency is high, indirect costs are considered and its price is lowered.
- | Journal: Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. (Pubmed Central) - Jul 30, 2021
Multiple clinical trials of the CGRP monoclonal antibodies and gepants, and now some open-label long-term extension data, established their efficacy, safety, and tolerability. In this chapter, we summarize the major clinical trials, pharmacokinetic insights, safety and tolerability profiles, and real-world data (if available) of the CGRP monoclonal antibodies and gepants.
- | sumatriptan succinate / Generic mfg.
Journal: Migraine Prophylaxis Using Novel Monoclonal Antibody Injections in a Commercial Pilot. (Pubmed Central) - Jul 30, 2021
Upon presentation, he was not flying due to his frequent headaches and he was started on monthly subcutaneous injections of fremanezumab...Aerosp Med Hum Perform. 2020; 91(10):824825.
- || Austedo (deutetrabenazine) / Teva, Ajovy (fremanezumab) / Otsuka, Teva
Teva taps new North American commercial chief as key meds Ajovy, Austedo lag their rivals https://t.co/TMILGogOhg (Twitter) - Jul 21, 2021
- || Ajovy (fremanezumab) / Otsuka, Teva
Review, Journal: 1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress. (Pubmed Central) - Jul 17, 2021
An update was also presented of the latest developments in the treatment of migraine with fremanezumab, a monoclonal antibody recently authorised by the European Medicines Agency...Finally, the repercussions of migraine in terms of its burden on the care and economic resources of the health system were addressed, along with its impact on society. The meeting summarised the content presented at the 14th EHF Congress, which took place in late June/early July 2020.
- |||| Ajovy (fremanezumab) / Otsuka, Teva
Clinical: Fremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine.@EHF_Official @ihs_official @EMHAlliance @hmru_cph https://t.co/WbZq4HAqMu (Twitter) - Jul 16, 2021
- || Clinical, Review, Journal: Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information. (Pubmed Central) - Jul 14, 2021
Head-to-head comparative studies with current guideline-recommended treatments are needed. However, CGRP antagonists are promising agents that present an alternative solution for patients living with migraine.
- ||| Ajovy (fremanezumab) / Otsuka, Teva
Clinical, P3 data, Clinical Trial,Phase III, Journal: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. (Pubmed Central) - Jul 13, 2021
P3
However, CGRP antagonists are promising agents that present an alternative solution for patients living with migraine. Fremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine and documented inadequate response to multiple migraine preventive medication classes.
- | Ajovy (fremanezumab) / Otsuka, Teva
Preclinical, Journal: Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. (Pubmed Central) - Jul 8, 2021
Fremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine and documented inadequate response to multiple migraine preventive medication classes. Our inability to detect fluorescent (CGRP-mAbs) in the brain supports the conclusion that CGRP-mAbs prevent the headache phase of migraine by acting mostly, if not exclusively, outside the brain as the amount of CGRP-mAbs that enters the brain (if any) is too small to be physiologically meaningful.
- || Review, Journal: Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? (Pubmed Central) - Jun 22, 2021
Importantly, they are effective in subgroups of patients who have failed previous preventive therapies. Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.
- | Journal: Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide (Pubmed Central) - Jun 22, 2021
This family of drugs: erenumab, galcanezumab, fremanezumab, eptinezumab, finished Fase III, extensions trials and many of them are in the market approved since 2018.Since 2019 are available in Argentina. We will describe the rationale for the prescription of this family of new drugs for migraine.
- || Retrospective data, Review, Journal: Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. (Pubmed Central) - Jun 16, 2021
No eligible studies have investigated eptinezumab...CGRP mAbs provide highly efficacious and safe outcomes which start early after the first injection. The tolerability of these medications surpasses that of other small-molecule CGRP antagonists.
- ||| Ajovy (fremanezumab) / Otsuka, Teva
A phase 2 study failed to find a benefit of fremanezumab treatment in persistent posttraumatic #headache. "That’s sad. It’s just dreadful news," said @StewartTepper. https://t.co/54tiG8CbQ7 (Twitter) - Jun 14, 2021
- ||||| Ajovy (fremanezumab) / Otsuka, Teva
Clinical: Open Access: Reduction in the severity & duration of #headache following #fremanezumab treatment in patients w episodic & #chronicmigraine @MessoudAshina @MyHeadacheDoc Sanjay K Gandhi PhD, Evelyn Du PhD #CGRP #migraine https://t.co/urw5dDgb2n (Twitter) - Jun 11, 2021
- ||| Ajovy (fremanezumab) / Otsuka, Teva
Teva, after locking up new Ajovy patents, sues Eli Lilly again in heated migraine drug fight https://t.co/PRjvW9D5Xo (Twitter) - Jun 9, 2021
- | Ajovy (fremanezumab) / Otsuka, Teva
Preclinical, Journal: Electro-acupuncture inhibits C-fiber-evoked WDR neuronal activity of the trigeminocervical complex: neurophysiological hypothesis of a complementary therapy for acute migraine rats. (Pubmed Central) - Jun 8, 2021
This study provides pioneering evidence of a potential neurobiological mechanism for the analgesic effect on migraine attacks achieved by electro-acupuncture intervention via DNIC. The data indicates that EA may become a crucial supplementary and alternative therapy for migraineurs that failed to respond to acute medications, e.g., fremanezumab, which achieves its analgesic effect via modulating Aσ-fibers, not C-fibers.
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Review, Journal: Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis. (Pubmed Central) - Jun 8, 2021
BoNT-A might be preferentially selected owing to its cost-effectiveness profiles. Further studies with direct comparison of the two treatments are warranted.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_389;
In this real-world study, onabotulinumtoxinA was effective at reducing MHD and the addition of a CGRP mAb was well tolerated and associated with incremental and clinically meaningful reductions in MHD for those who were able to stay on the combination. No new safety signals were identified.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Evaluation of the correlations between pretreatment plasma CGRP levels, disease characteristics and fremanezumab treatment response in patients with posttraumatic headache () - Jun 4, 2021 - Abstract #AHS2021AHS_370;
P1, P2
However, the absence of correlations between CGRP and clinical characteristics and treatment response to an antibody against CGRP suggest that such associations may be weak at best, especially in plasma which contains many sources of CGRP or may be more relevant to a specific subpopulation or clinical subtype of PTH. The varied pathophysiology and clinical presentation of PTH and the limited sample size are significant limitations of this study.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for control of chronic migraine in patients meeting American Headache Society criteria who received calcitonin generelated peptide monoclonal antibody therapy added to OnabotulinumtoxinA () - Jun 4, 2021 - Abstract #AHS2021AHS_365;
This was a retrospective, longitudinal chart review of adults with CM treated at 1 clinic (October 2018November 2019) with 2 consecutive onabotulinumtoxinA cycles before 1 month of onabotulinumtoxinA plus CGRPmAb (erenumab, fremanezumab, or galcanezumab) combination treatment. Combination use of onabotulinumtoxinA and CGRPmAb demonstrated clinically meaningful improvements in headache frequency and migraine-related disability compared with onabotulinumtoxinA alone in patients with high baseline MHDs and disability treated according to AHS guidance.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway () - Jun 4, 2021 - Abstract #AHS2021AHS_340;
In this real-world study of migraine patients who had previously discontinued another anti-CGRP, fremanezumab resulted in sustained clinically meaningful reductions in MMD and MHD over up to 6 months. Similar reductions in MMD and MHD were observed in patients who had no prior anti-CGRP treatment.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] No evidence of wearing off effect for fremanezumab treatment in chronic and episodic migraine patients with inadequate response to 24 prior classes of migraine preventive medications () - Jun 4, 2021 - Abstract #AHS2021AHS_339;
Fremanezumab treatment resulted in consistent reductions in weekly migraine days over up to 6 months of treatment in CM and EM patients with inadequate response to multiple prior migraine preventive medication classes. There was no evidence of a wearing-off effect towards the end of the dosing interval for quarterly fremanezumab during the DBP or for monthly fremanezumab throughout the DBP and OLE.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Clinically meaningful responses to fremanezumab treatment in episodic and chronic migraine over up to 15 months () - Jun 4, 2021 - Abstract #AHS2021AHS_338;
There was no evidence of a wearing-off effect towards the end of the dosing interval for quarterly fremanezumab during the DBP or for monthly fremanezumab throughout the DBP and OLE. Both quarterly and monthly fremanezumab were effective in achieving lasting clinically meaningful response in EM and CM, based on the reduction from baseline in MMD, the duration of this response, and the proportion of participants with sustained response over 15 months.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Sustained, clinically meaningful responses to fremanezumab treatment in migraine patients with inadequate response to 24 prior classes of migraine preventive medications () - Jun 4, 2021 - Abstract #AHS2021AHS_334;
Both quarterly and monthly fremanezumab were effective in achieving lasting clinically meaningful response in EM and CM, based on the reduction from baseline in MMD, the duration of this response, and the proportion of participants with sustained response over 15 months. Fremanezumab treatment resulted in sustained clinically meaningful responses over 6 months in patients with EM or CM and inadequate response to multiple prior migraine preventive medication classes.
- atogepant (AGN-241689) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: A systematic literature review and network meta-analysis () - Jun 4, 2021 - Abstract #AHS2021AHS_320;
The evidence base consisted of placebo-controlled trials including the following treatments: rimegepant 75mg (oral tablet, every other day [EOD]), atogepant 10mg (oral, daily), 30mg (one or twice daily), 60mg (one or twice daily), erenumab 70mg, 140mg (subcutaneous injection [SC] monthly), galcanezumab 120mg, 240mg (SC, monthly), eptinezumab 30mg, 100mg, 300mg (intravenous infusion [IV], quarterly), and fremanezumab 225mg (SC, monthly), 675mg (SC, quarterly). Rimegepant, atogepant, and mAbs were all effective treatment options for the prevention of migraine when compared vs. placebo and generally showed similar effects when compared to one another.
- Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Crowdsourcing post-marketing safety surveillance for migraine preventives: Self-reported adverse events associated with calcitonin gene-related peptide (CGRP) therapeutics on a social media forum () - Jun 4, 2021 - Abstract #AHS2021AHS_299;
Computational linguistics applied to social media can identify potential adverse events of interest for migraine preventives. Further studies are needed to explore side effects and safety of the novel CGRP medications.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_275;
Patients who trial a CGRP MAB may experience a wear-off phenomenon that is equal to approximately 25% of the anticipated time of therapeutic benefit (8 out of 30 days). Clinicians may consider documenting the use and benefit of bridge therapies during the wear-off period, and may also consider trialing a different CGRP MAB if wear-off has been identified.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Patient preferences for self-injectable preventive treatments for migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_269;
Preferences for autoinjectors were driven by injection duration, auto-retractability of needle removal, storage requirements and the type of autoinjector base and pinching requirements. Among self-injectable migraine preventive treatments, participants preferred a profile similar to that of galcanezumab.